Download PDF
Thromb Haemost 1988; 60(02): 255-261
DOI: 10.1055/s-0038-1647041
Original Article
Schattauer GmbH Stuttgart

The Influence of Carbohydrate Structure on the Clearance of Recombinant Tissue-Type Plasminogen Activator

A Hotchkiss
1   The Department of Pharmacological Sciences, Genentech, Inc., South San Francisco, CA, USA
,
C J Refino
1   The Department of Pharmacological Sciences, Genentech, Inc., South San Francisco, CA, USA
,
C K Leonard
2   The Department of Medicinal and Analytical Chemistry, Genentech, Inc., South San Francisco, CA, USA
,
J V O'Connor
2   The Department of Medicinal and Analytical Chemistry, Genentech, Inc., South San Francisco, CA, USA
,
C Crowley
3   The Department of Cell Genetics, Genentech, Inc., South San Francisco, CA, USA
,
J McCabe
1   The Department of Pharmacological Sciences, Genentech, Inc., South San Francisco, CA, USA
,
K Tate
4   The Department of Molecular Biology, Genentech, Inc., South San Francisco, CA, USA
,
G Nakamura
2   The Department of Medicinal and Analytical Chemistry, Genentech, Inc., South San Francisco, CA, USA
,
D Powers
4   The Department of Molecular Biology, Genentech, Inc., South San Francisco, CA, USA
,
A Levinson
4   The Department of Molecular Biology, Genentech, Inc., South San Francisco, CA, USA
,
M Mohler
1   The Department of Pharmacological Sciences, Genentech, Inc., South San Francisco, CA, USA
,
M W Spellman
4   The Department of Molecular Biology, Genentech, Inc., South San Francisco, CA, USA
› Author Affiliations
Further Information

Publication History

Received 21 March 1988

Accepted after revision 13 June 1988

Publication Date:
28 June 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Modification of the carbohydrate structures of recombinant tissue-type plasminogen activator (rt-PA) can increase or decrease its rate of clearance in rabbits. When rt-PA was treated with sodium periodate to oxidize carbohydrate residues, the rate of clearance was decreased from 9.6 ± 1.9 ml min−1 kg−1 to 3.5 ± 0.6 ml min−1 kg−1 (mean ± SD, n = 5). A similar change in the clearance of rt-PA was introduced by the use of endo-β-N-acetyl- glucosaminidase H (Endo-H), which selectively removes high mannose asparagine-linked oligosaccharides; the clearance of Endo-H-treated rt-PA was 5.0 ± 0.5 ml min−1 kg−1. A mutant of rt-PA was produced with an amino acid substitution at position 117 (Asn replaced with Gin) to remove a potential glycosylation site that normally contains a high mannose structure. The clearance of this material was also decreased, similar to the periodate and Endo-H-treated rt-PA. Conversely, when rt-PA was produced in the CHO 15B cell line, which can produce only high mannose oligosaccharide structures on glycoproteins, the clearance was increased by a factor of 1.8. These results demonstrate that the removal of rt-PA from the blood depends significantly upon the nature of its oligosaccharide structures.

Keywords

Tissue-type plasminogen activator - Plasminogen activator - Pharmacokinetics - CHO 15 B cells - High mannose oligosaccharides
 

  • References

  • 1 Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin.. J Biol Chem 1982; 257: 2912-2919
    PubMedSearch in Google Scholar
  • 2 Rijken DC, Hoylaerts M, Collen D. Fibrinolytic properties of one- chain and two-chain human extrinsic (tissue-type) plasminogen activator.. J Biol Chem 1982; 257: 2920-2925
    PubMedSearch in Google Scholar
  • 3 Rijken DC, Wijngaards G, Zaal-de JongM, Welbergen J. Purification and partial characterization of plasminogen activator from human uterine tissue.. Biochim Biophys Acta 1979; 580: 140-153
    CrossrefPubMedSearch in Google Scholar
  • 4 Binder BR, Spragg J, Austen KF. Purification and characterization of human vascular plasminogen activator derived from blood vessel perfusates.. J Biol Chem 1979; 254: 1998-2003
    PubMedSearch in Google Scholar
  • 5 Rijken DC, Collen D. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture.. J Biol Chem 1981; 256: 7035-7041
    PubMedSearch in Google Scholar
  • 6 Wallen P, Pohl G, Bergsdorf N, Ranby M, Ny T, Jornvall H. Purification and characterization of a melanoma cell plasminogen activator.. Eur J Biochem 1983; 132: 681-686
    CrossrefPubMedSearch in Google Scholar
  • 7 Pennica D, Holmes WE, Kohr WJ, Harkins RN, Vehar GA, Ward CA, Bennett WF, Yelverton E, Seeburg PH, Heyneker HL, Goeddel DV, Collen D. Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. . Nature (London) 1983; 301: 214-221
    CrossrefPubMedSearch in Google Scholar
  • 8 Williams DO, Borer J, Braunwald E, Chesebro JH, Cohen LS, Dalen J, Dodge HT, Francis CK, Knatterud G, Ludbrook P, Markis JE, Mueller H, Desvigne-Nickens P, Passamani ER, Powers ER, Rao AK, Roberts R, Ross A, Ryan TJ, Sobel BE, Winniford M, Zaret B. Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction: a report from the NHLBI thrombolysis in myocardial infarction trial. Circulation 1986; 73: 338-346
    CrossrefPubMedSearch in Google Scholar
  • 9 Graor RA, Risius B, Lucas FV, Young JR, Ruschhaupt WF, Beven EG, Grossbard EB. Thrombolysis with recombinant human tissue- type plasminogen activator in patients with peripheral artery and bypass graft. Circulation 1986; 74 (suppl 1) 115-120
    PubMedSearch in Google Scholar
  • 10 Collen D, Bounameaux H, De CockF, Lijnen HR, Verstraete M. Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. Circulation 1986; 73: 511-517
    CrossrefPubMedSearch in Google Scholar
  • 11 The thrombolysis in myocardial infarction (TIMI) trial. Phase I findings. TIMI Study Group. New Engl J Med 1985; 312: 932-936
    PubMedSearch in Google Scholar
  • 12 Risius B, Graor RA, Geisinger MA, Zelch MG, Lucas FV, Young JR, Grossbard EB. Recombinant human tissue-type plasminogen activator for thrombolysis in peripheral arteries and bypass grafts.. Radiology 1986; 160: 183-188
    CrossrefPubMedSearch in Google Scholar
  • 13 Goldhaber SZ, Vaughan DE, Markis JE, Selwyn AP, Meyerovitz MF, Loscalzo J, Kim DS, Kessler CM, Dawley DL. et al Acute pulmonary embolism treated with tissue plasminogen activator.. Lancet 1986; 2: 886-899
    PubMedSearch in Google Scholar
  • 14 Korninger C, Stassen JM, Collen D. Turnover of human extrinsic (tissue-type) plasminogen activator in rabbits.. Thromb Haemostas 1981; 46: 658-661
    PubMedSearch in Google Scholar
  • 15 Nilsson S, Einarsson M, Ekvarn S, Haggroth L, Mattsson CH. Turnover of tissue plasminogen activator in normal and hepatectomized rabbits.. Thromb Res 1985; 39: 511-521
    CrossrefPubMedSearch in Google Scholar
  • 16 Bounameaux H, Stassen JM, Seghers C, Collen D. Influence of fibrin and liver blood flow on the turnover and the systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator in rabbits.. Blood 1986; 67: 1493-1497
    PubMedSearch in Google Scholar
  • 17 Baughman RA. Pharmacokinetics of tissue plasminogen activator.. In: Tissue Plasminogen Activator in Thrombolytic Therapy. Sobel B, Grossbard E, Collen D. (eds) Marcel Dekker; New York : 1987. pp 41-53
    Search in Google Scholar
  • 18 Verstraete M, Bounameaux H, De CockF, Van De WerfF, Collen D. Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in humans.. J Pharm Exp Ther 1985; 235: 506-512
    PubMedSearch in Google Scholar
  • 19 Ashwell G, Hartford J. Carbohydrate-specific receptors in the liver.. Annu Rev Biochem 1982; 51: 531-554
    CrossrefPubMedSearch in Google Scholar
  • 20 Spellman MW, Ferguson CK, O’Connor JV. Characterization of N-linked oligosaccharides from recombinant tissue-type plasminogen activator. XHIth Int Carbohydrate Symposium, Abstr B122. 1986
    Search in Google Scholar
  • 21 Pohl G, Kenne L, Nilsson B, Einarsson M. Isolation and characterization of three different carbohydrate chains from melanoma tissue plasminogen activator.. Eur J Biochem 1987; 170: 69-75
    CrossrefPubMedSearch in Google Scholar
  • 22 Fuchs HE, Berger H, Pizzo SV. Hepatic clearance of tissue-type plasminogen activator in rats.. Blood 1985; 65: 539-544
    PubMedSearch in Google Scholar
  • 23 Emeis JJ, van den HoogenCM, Jense D. Hepatic clearance of tissue-type plasminogen activator in rats.. Thromb Haemostas 1985; 54: 661-664
    PubMedSearch in Google Scholar
  • 24 Einarsson M, Smedsrod B, Pertoft H. Endocytosis of tissue plasminogen activator (t-PA) by rat liver cells.. Thromb Haemostas 1985; 54: 270 (Abstr).
    PubMedSearch in Google Scholar
  • 25 Bakhit C, Lewis D, Billings R, Malfroy B. Cellular catabolism of recombinant tissue-type plasminogen activator. Identification and characterization of a novel high affinity uptake system on rat hepatocytes.. J Biol Chem 1987; 262: 8716-8720
    PubMedSearch in Google Scholar
  • 26 Li E, Kornfeld S. Structure of the altered oligosaccharide present in glycoproteins from a clone of Chinese hamster ovary cells deficient in N-acetylglucosaminyltransferase activity.. J Biol Chem 1978; 253: 6426-6431
    PubMedSearch in Google Scholar
  • 27 Graham FL, Van Der EBA. A new technique for the assay of infectivity of human adenovirus 5 DNA.. Virology 1973; 52: 456-467
    CrossrefPubMedSearch in Google Scholar
  • 28 Albersheim P, Nevins DJ, English PD, Karr A. A method for the analysis of sugars in plant cell-wall polysaccharides by gas-liquid chromatography. Carbohydrate Res 1967; 5: 340-345
    CrossrefPubMedSearch in Google Scholar
  • 29 Nesser JR, Schweizer JF. A quantitative determination by capillary gas-liquid chromatography of neutral and amino sugars (as o-methyloxime acetates), and a study on hydrolytic conditions for glycoproteins and polysaccharides in order to increase sugar recoveries.. Anal Biochem 1984; 142: 58-67
    CrossrefPubMedSearch in Google Scholar
  • 30 Mohler MA, Refino CJ, Chen SA, Chen AB, Hotchkiss AJ. D-Phe-Pro-Arg-chloromethylketone: its potential use in inhibiting the formation of in vitro artifacts in blood collected during tissue-type plasminogen activator thrombolytic therapy.. Thromb Haemostas 1986; 56: 160-164
    PubMedSearch in Google Scholar
  • 31 Benninger A, Baughman B. FEATHER, an interactive curve stripping program. Pharm Res 1986; 3: 120s
    PubMedSearch in Google Scholar
  • 32 Gibaldi M, Perrier D. Pharmacokinetics.. Marcel Dekker Inc.; New York : 1982. 2nd ed, pp 433-444
    Search in Google Scholar
  • 33 Tolleshaug H, Berg T, Blomhoff R. Uptake of mannose-terminated glycoproteins in isolated rat liver cells. Evidence for receptor-mediated endocytosis in hepatocytes.. Biochem J 1984; 223: 151-160
    CrossrefPubMedSearch in Google Scholar
  • 34 Collen D, Tytgat G, Verstraete M. Semi-automatic method for routine evaluation of fibrinolytic components.. J Clin Pathol 1968; 21: 705-707
    CrossrefPubMedSearch in Google Scholar
  • 35 Collen D, Stassen JM, Marafino BJ, Builder S, DeCock F, Ogez J, Tajiri D, Pennica D, Bennett WF, Salwa J. et al. Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells.. J Pharm Exp Ther 1984; 231: 146-152
    PubMedSearch in Google Scholar
  • 36 Mohler MA, Tate K, Bringman TS, Fuller G, Keyt B, Vehar G, Hotchkiss AJ. Circulatory metabolism of recombinant tissue-type plasminogen activator in monkeys and rabbits. Fibrinolysis 1988; 2: 17-23
    PubMedSearch in Google Scholar